NEW NUCLEOTIDE SEQUENCES

Abstract: The present invention relates to a nucleic acid molecule encoding a GABAB receptor, or a functionally equivalent modified form thereof, said receptor being selected from the group consisting of human and canine GABAB receptors.

Description: NEW NUCLEOTIDE SEQUENCES TECHNICAL FIELD The present invention relates in particular to nucleic acid molecules encoding GABAB receptors, and to methods for screening for compounds which are inhibitors of transient lower esophageal sphincter relaxations (TLESR), said methods comprising the use of a nucleic acid molecule encoding a GABAB receptor. BACKGROUND ART GABAg receptors GAB A (4-aminobutanoic acid) is an endogenous neurotransmitter in the central and peripheral nervous systems. Receptors for GABA have traditionally been divided into GABA A and GABAB receptor subtypes. GABA B receptors (for a review see Kerr, D.I.B. and Ong, J. (1995) Pharmac. Ther. vol. 67, pp.187-246) belong to the superfamily of G- protein coupled receptors. GABAB receptor agonists are described as being of use in the treatment of CNS disorders, such as muscle relaxation in spinal spasticity, cardiovascular disorders, asthma, gut motility disorders such as irritable bowel syndrome and as prokinetic and anti-tussive agents. GABAB receptor agonists have also been disclosed as useful in the treatment of emesis (WO 96/11680). The cloning of the rat GABA B receptors GABA B Rla (SEQ ID NOS: 44 and 45) and GABA β Rlb (SEQ ID NOS: 46 and 47) is disclosed by Kaupmann et al. (1997) Nature, vol. 386, 239-246. The mature rat GABA B Rlb differed from GABA B Rla in that the N- terminal 147 residues were replaced by 18 different residues. It was presumed that the rat GABA β Rla and -b receptor variants are derived from the same gene by alternative splicing. The cloning of the human GABA B receptor GABA B Rlb is disclosed in WO 97/46675. ~~ Reflux In some humans, the lower esophageal sphincter (LES) is prone to relaxing more frequently than in other humans. As a consequence, fluid from the stomach can pass into the esophagus since the mechanical barrier is temporarily lost at such times, an event hereinafter referred to as "reflux". Gastro-esophageal reflux disease (GERD) is the most prevalent upper gastrointestinal tract disease. Current therapy has aimed at reducing gastric acid secretion, or by reducing esophageal acid exposure by enhancing esophageal clearance, lower esophageal sphincter tone and gastric emptying. The major mechanism behind reflux has been considered to depend on a hypotonic lower esophageal sphincter. However, recent research (e.g. Holloway & Dent (1990) Gastroenterol. Clin. N. Amer. 19, 517-535) has shown that most reflux episodes occur during transient lower esophageal sphincter relaxations (TLESR), i.e. relaxations not triggered by swallows. It has also been shown that gastric acid secretion usually is normal in patients with GERD. Consequently, there is a need for compounds which reduce the incidence of TLESR and thereby prevent reflux. DISCLOSURE OF THE INVENTION In the applicants' earlier patent application WO 98/11885, filed on 15 September 1997, it is disclosed that GABAB receptor agonists can be used to reduce the incidence of transient lower esophageal sphincter relaxations (TLESR). The present invention provides nucleic acid molecules encoding human and canine GABAB receptors. These nucleic acid molecules will make possible the screening for compounds which are agonists or antagonists of GABAB receptors, e.g. compounds which are inhibitors of transient lower esophageal sphincter relaxations (TLESR). Consequently, in a first aspect, the present invention provides a nucleic acid molecule ~ encoding a GABAB receptor, or a functionally equivalent modified form thereof, said receptor being selected from the group consisting of human and canine GABA B receptors. In preferred forms of the invention, the said nucleic acid molecule encodes the human GABA B receptor la (SEQ ID NOS: 48 and 49), lb (SEQ ID NOS: 50 and 51), lc (SEQ ID NOS: 54 and 55) or Id (SEQ ID NOS: 56 and 57); or the canine GABA B receptor la (SEQ ID NOS: 52 and 53) or lc (SEQ ID NOS: 58 and 59). Accordingly, the invention furthermore provides a nucleic acid molecule selected from: (a) nucleic acid molecules comprising a nucleotide sequence set forth as SEQ ID NO: 48, 50, 52, 54, 56 or 58; (b) nucleic acid molecules comprising a nucleotide sequence capable of hybridizing, under stringent hybridization conditions, to a nucleotide sequence complementary to the polypeptide coding region of a DNA molecule as defined in (a); and (c) nucleic acid molecules comprising a nucleotide sequence which is degenerate as a result of the genetic code to a nucleotide sequence as defined in (a) or (b). Furthermore, the invention provides nucleic acid molecules of genomic origin encoding human GABA B receptors (SEQ ID NOS: 60 and 61) as well as nucleic acid molecules (set forth as SEQ ID NO: 70, 72, 74, 76, 78, 80, 82, 84) encoding additional isofor s of the human GABA B receptor which isoforms can be shown to be generated by alternative splicing. It should thus be understood that the nucleic acid molecule according to the invention is not to be limited strictly to molecules comprising the sequences set forth as SEQ ID : 48, 50, 52, 54, 56 or 58. Rather the invention encompasses nucleic acid molecules carrying modifications like substitutions, small deletions, insertions or inversions, which nevertheless encode proteins having substantially the biochemical activity of the GABAB receptors according to the invention. Included in the invention are consequently nucleic acid molecules, the nucleotide sequence of which is at least 95% homologous, preferably at least 96%, 97%, 98% or 99% homologous, with the nucleotide sequence shown as SEQ ID NO: 48, 50, 52, 54, 56 or 58 in the Sequence Listing. The term "stringent hybridization conditions" is known in the art from standard protocols (e.g. Current Protocols in Molecular Biology, editors F. Ausubel et al., John Wiley and Sons, Inc. 1994) and could be understood as as stringent or more stringent than those defined by e.g. hybridization to filter-bound DNA in 0.5 M NaHPO 4 , 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at +65°C, and washing in O.lxSSC / 0.1% SDS at +68°C. Included in the invention is also a nucleic acid molecule which nucleotide sequence is degenerate, because of the genetic code, to a nucleic acid of the present invention and more particularly to one of the nucleotide sequences set forth as SEQ ID NOs: 48, 50, 52, 54, 56 and 58. A sequential grouping of three nucleotides, a "codon", codes for one amino acid. Since there are 64 possible codons, but only 20 natural amino acids, most amino acids are coded for by more than one codon. This natural "degeneracy", or "redundancy", of the genetic code is well known in the art. It will thus be appreciated that the nucleic acid sequences shown in the Sequence Listing is only an example within a large but definite group of nucleic acid sequences which will encode the polypeptide as described above. In a further aspect, the invention provides a recombinant polypeptide encoded by a nucleotide sequence of the present invention, encoding a GAB A B receptor. In preferred forms of the inventions, the said polypeptide comprises an amino acid sequence set forth as SEQ ID NO: 49, 51, 53, 55, 57, 59, 71, 73, 75, 77, 79, 81, 83 or 85 in the Sequence Listing. However, polypeptides of the present invention are not to limited to those having an amino acid sequence identical with one of SEQ ID NOs: 49, 51, 53, 55, 59, 71, 73, 75, 77, 79, 81 , 83 or 85 in the Sequence Listing. Rather the invention encompasses polypeptides carrying modifications such as substitutions, small deletions, insertions or inversions, which polypeptides nevertheless have substantially the biological activities of the GABAg receptor. Included in the invention are consequently polypeptides, the amino acid sequence of which is at least 95% homologous, preferably at least 96%, 97%, 98% or 99% homologous, with one of the amino acid sequences described by SEQ ID NOs: 49, 51, 53, 55, 57 59, 71, 73, 75, 77, 79, 81, 83 and 85 in the Sequence Listing. Included in the invention are polypeptides of the present invention which have been post- translationally modified, e.g. by cleavage of an N-terminal signal sequence which can be e.g. 1 to 25 amino acids long. In yet another aspect, the invention provides a vector transformed with a nucleic acid molecule of the present invention. The said vector can e.g. be a replicable expression vector which carries and is capable of mediating the expression of a nucleic acid molecule according to the invention. In the present context the term "replicable" means that the vector is able to replicate in a given type of host cell into which is has been introduced. Examples of vectors are viruses such as bacteriophages, cosmids, plasmids and other recombination vectors. Nucleic acid molecules are inserted into vector genomes by methods well known in the art. Included in the invention is also a cultured host cell harbouring a vector according to the invention. Such a host cell can be a prokaryotic cell, a unicellular eukaryotic cell or a cell derived from a multicellular organism. The host cell can thus e.g. be a bacterial cell such as an E. coli cell; a cell from a yeast such as Saccharomyces cervisiae or Pichia pastoris, or a mammalian cell. The methods employed to effect introduction of the vector into the host cell are standard methods well-known to a person familiar with recombinant DNA methods. A further aspect of the invention is a process for production of a GAB A B receptor polypeptide according to the invention, said process comprising culturing a host cell as defined above under conditions whereby the said polypeptide is produced, and recovering the said polypeptide. A further important aspect of the invention is a method for the screening of compounds which are inhibitors of transient lower esophageal sphincter relaxations (TLESR), said method comprising the use of a nucleic acid molecule encoding a GABA B receptor. The said nucleic acid molecule encoding a GABAB receptor can e.g. be one of the nucleic acid molecules according to the invention encoding human or canine GABAB receptors. However, it should be understood that this aspect of the invention is not limited to the use of the said human and canine GAB A B receptors, but rather encompasses the use of any GABAB receptor for screening for compounds which are inhibitors of transient lower esophageal sphincter relaxations. In yet another important aspect, the invention provides a method for the screening of compounds which are agonists or antagonists to a GABAB receptor, said method comprising the use of a nucleic acid molecule, according to the invention, encoding human or canine GABAB receptors. Brief Description of the Drawings Figure 1 : Map of the human GAB A B receptor gene. The exon intron organisation is shown. Exons are indicated as solid boxes numbered 1-23. The part of intron 5 that is retained together with exon 6 giving rise to GABA B receptor lb is indicated as an open box. Figure 2: Expression of human GABA B receptor lb isoform in transfected C127 cells. Western blot analysis of transfected C127 cells using a polyclonal anti-human GABA B receptor antibody. Lane 1: Untransfected C127 whole cell lysate. Lanes 2-7: Whole cell lysates of six independent clones transfected with human GABA B receptor lb isoform encoding cDNA. The clones analysed in lanes 4 to 7 express a GABA B receptor of expected molecular weight (arrow). Figure 3: Expression of human GABA B receptor Id isoform in transfected C127 cells. Western blot analysis of transfected C127 cells using a polyclonal anti-human GABA B receptor antibody. Lanes 1-3: Concentrated culture media from three independent C127 clones transfected with a cDNA expression construct encoding the human GABA B receptor Id isoform. Lanes 4-6: Whole cell lysates corresponding to the clones analysed in lanes 1- 3. The experiment revealed that the human GABA B receptor Id cDNA encodes a secreted isoform. The arrow indicates the bands corresponding to the Id isoform. Figure 4: Expression of human GABA B receptor Id isoform in E. coli. Western blot analysis of transformed E. coli cells using a polyclonal anti-human GABA B receptor antibody. Lane 1: Lysate from an uninducedE. coli culture transformed with an pΕT-based expression construct encoding the human GABA B receptor Id cDNA. Lane 2: Lysate from an IPTG-inducedE. coli culture transformed with an expression construct encoding the human GABA B receptor Id cDNA. Lane 3: Lysate from an IPTG-induced E. coli culture transformed with an expression construct encoding an unrelated protein. Lane 4: The BSA-conjugated peptide previously used for immunization was loaded on the gel as a positive antibody control. The screening methods according to the invention can e.g. comprise the steps (a) transforming a cultured cell with a nucleic acid molecule encoding a GABA B receptor, so that a GABA B receptor is expressed on the surface of the cell; (b) contacting a test compound with the said cell; and (c) determining whether the test compound binds to, and/or activates, the GABAB receptor. In particular GABA B receptor expressing cells, transgenic animals or cells and tissues derived thereof, nay be used to screen substance libraries for antagonist or agonist activities. For this purpose, GABA B receptor expression may be directed to cells and tissues containing, either naturally or artificially, the necessary components allowing correct receptor transport and processing as well as coupling to second messenger pathways. Screening may be performed as ligand binding assays or functional assays. For screening, cells and tissues my be prepared in various ways, each uniquely suited to its purpose. Ligand binding assays are performed in vivo or in vitro using e.g. radiolabelled GABA. Functional assays examplified by, but not limited to, Ca^-responses, cAMP- SUBSTITUTΕ SHEET (RULE 26) responses and effects on K + channels, may be performed in living cells, broken cells, isolated cell membranes, as well as in tissues and in living animals. To facilitate measurement of physiological GABA B receptor mediated responses, GABA B receptors may be co-expressed with promiscous G-proteins like e.g. G l6 or Gqi5 increasing G- protein coupling. Another possible way to increase G-protein coupling is to fuse the GABA B receptor with appropriate G-proteins using standard molecular techniques. In order to further improve readouts in Ca^-response assays, GABA B receptors may be co- expressed with aequorin, a photoprotein cloned from the luminescent jellyfish Aequorea victoria. In yet another aspect, the invention provides a pharmaceutical compositions comprising a soluble GABA B receptor further comprising one or more pharmaceutical acceptable carriers and/or diluents. In yet another aspect, the invention provides a method for the diagnosis or treatment of conditions related to GABA-dysfunction, e.g. epilepsy, psychiatric disorders such as depression and anxiety, cognitive dysfunction, gastroesophageal reflux disease, emesis, irritable bowel syndrome, dyspepsia, spasticity, arthritis, allergies, autoimmune diseases, neoplastic diseases, pain, and infectious diseases, comprising the use or administration of soluble forms of the GABA B receptor, such as the human GABA B receptor lc or Id or functionally equivalent modified forms thereof; preferably being a polypeptidfe of the present invention.. The soluble forms of the GABA B receptor can e.g. be produced by culturing a host cell harbouring a vector comprising a nucleic acid encoding the soluble GABA B receptor under conditions where whereby the said polypeptide is produced, the polypeptide recovered and administered to a patient in need thereof. Furthermore, the level of soluble GABA B receptors in certain body fluids, e.g. serum and CSF, can be measured and used in diagnostics related to conditions with altered levels of soluble GABA B receptors in said body fluids. Throughout this description the terms "standard protocols" and "standard procedures", when used in the context of molecular cloning techniques, are to be understood as protocols and procedures found in an ordinary laboratory manual such as: Current Protocols in Molecular Biology, editors F. Ausubel et al., John Wiley and Sons, Inc. 1994, orSambrook, J., Fritsch, E.F. and Maniatis, T., Molecular Cloning: A laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989. EXAMPLES EXAMPLE 1A: Cloning and sequencing of cDNA encoding human GABAB receptor la and lb Messenger RNA from human hippocampus was obtained from Clontech (Palo Alto, CA, USA) (catalog #6578-1). First-strand cDNA synthesis reactions were performed using the First-strand cDNA Synthesis kit from Amersham Pharmacia Biotech (Uppsala, Sweden). The pd(N) 6 primer was used to prime the first-strand synthesis. The generated cDNA molecules were used as template in the PCR reactions described below. Specific PCR primers were designed (Table 1) based on the sequences of the rat GABAβ receptor la and lb cDNA (Kaupmann et al. 1997, EMBL accession numbers Y10369 (SEQ ID NO: 44) and Y10370 (SEQ ID NO: 46)). TABLE 1 Primers used for RT-PCR on mRNA from human hippocampus cDNA fragments encoding parts of the human GABA B receptors were amplified directly by PCR using the designed primers with the generated cDNA molecules as templates. All PCR experiments were carried out using the Perkin Elmer Taq DNA polymerase with Gene Amp (Roche Molecular Systems Inc., NJ, USA) with the following PCR program: +95°C for 1 minute, +50°C for 30 seconds, +72°C for 3 minutes, repeated 44 times and finally +72°C for 7 minutes. The following primer combinations gave PCR products with expected sizes: 838 and 842, 838 and 795, 797 and 865, 864 and 865, 864 and 863 which corresponds to the 5 '-end of the GABA B receptor la. Primer pair 932 and 831 , 932 and 796, 794 and 831 gave PCR products which correspond to the 3 '-end of both GABA B receptor la and lb. The primer combination 839 and 918 gave a PCR product corresponding to the 5 '-end of the GABAB receptor lb. The PCR products were subcloned into the pGEM-T vector from Promega (Madison, USA). The inserts were subjected to nucleotide sequence analysis, the complete nucleotide sequence for all subclones were determined using a Thermo Sequenase dye terminator cycle sequencing pre-mix kit (Amersham Pharmacia Biotech, Uppsala, Sweden). As primers for sequencing reactions specific oligonucleotides complementary to the vector pGEM-T or primers complementary to the cDNA encoding the GABAB receptor were used. Additional PCR primers were designed based on the obtained sequences encoding fragments of the human GABA B receptor and additional DNA fragments encoding parts of the human GABA B receptors were amplified by PCR, the PCR products subcloned and sequenced as described above. EXAMPLE IB : Cloning and sequencing of the 3 '-ends of the cDNA encoding human GABA B receptors la and lb Messenger RNA from human hippocampus was obtained from Clontech (Palo Alto, CA, USA) (catalogue #6578-1). First strand cDNA synthesis reactions were performed using the First-strand cDNA Synthesis kit from Amersham Pharmacia Biotech (Uppsala, Sweden). The Not I-d(T)ι 8 primer was used to prime the first-strand synthesis. The generated cDNA molecules were used as template in the PCR reactions described below. Specific PCR primers were designed (Table 2 ) based on the sequences of the human GABA B receptor la and lb cDNA obtained in Example 1 A and the EST sequence EMBL accession number Yl 1044. By homology searches in the EMBL database using the GABA B receptor cDNA sequences obtained in Example 1A as query the EST sequence EMBL accession number Yl 1044 have been found to be homologous to the 3 '-end of the GABA B receptor cDNA. TABLE 2 Primers used in PCR to amplify 3 'ends of human GABA B receptor cDNA cDNA fragments encoding parts of the human GAB As receptors were amplified directly by PCR using the designed primers with the generated cDNA molecules as templates. All PCR experiments were carried out using the Perkin Elmer Taq DNA polymerase with Gene- Amp (Roche Molecular Systems Inc., NJ, USA) with the following PCR program: + 95°C for 1 minute, +50°C for 30 seconds,+72°C for 3 minutes, repeated 44 times and finally +72°C for 7 minutes. The following primer combinations gave PCR products with expected sizes: 938 and 972, 938 and 973 corresponding to the 3 'end of both GABA B receptor la and lb cDNA. The PCR products were subcloned into the pGEM-T vector from Promega (Madison, USA). The inserts were subjected to nucleotide sequence analysis, the complete nucleotide sequence for all subclones were determined using a Thermo Sequenase dye terminator cycle sequencing pre-mix kit (Amersham Pharmacia Biotech, Uppsala, Sweden). As primers for sequencing reactions specific oligonucleotides complementary to the vector pGEM-T or primers complementary to the cDNA encoding the GAB As receptor were used. EXAMPLE 1C : Cloning and sequencing of the 5 '-end of the cDNA encoding human GAB A B receptor lb Messenger RNA from human hippocampus was obtained from Clontech (Palo Alto, CA, USA) (catalogue #6578-1). Marathon cDNA amplification Kit (Clontech) was used for performing 573'- RACE (Rapid Amplification of cDNA Ends). Adaptor-ligated double stranded cDNA molecules were amplified according to the manufacturers description. The pd(N) 6 primer from the First-strand cDNA Synthesis kit from Amersham Pharmacia Biotech (Uppsala, Sweden) was used to produce the adaptor-ligated cDNA. A specific PCR primer was designed (Table 3) based on the sequences of the human GABA B receptor lb cDNA obtained in Example 1A. TABLE 3 Primers used in PCR to amplify the 5 '-ends of human GABA B receptor cDNA cDNA fragments encoding part of the human GABAs receptors were amplified directly by PCR using the designed primers with the generated adaptor-ligated cDNA molecules as template. The PCR experiment was carried out using the Expand Long Template PCR System (Boehringer Mannheim GmbH, Germany) with the following PCR program: + 94°C for 1 minute, + 94°C for 30 seconds, +60°C for 30 seconds, +68°C for 4 minutes, repeated 24 times. The primer combination API and 958 gave a PCR product which corresponded to the 5 '-end of the GABA B receptor lb cDNA, including 190 base pairs upstream the initiation codon. The PCR products were subcloned into the pGEM-T vector from Promega (Madison, USA). The inserts were subjected to nucleotide sequence analysis, the complete nucleotide sequence for all subclones were determined using a Thermo Sequenase dye terminator cycle sequencing pre-mix kit (Amersham Pharmacia Biotech, Uppsala, Sweden). As primers for sequencing reactions specific oligonucleotides complementary to the vector pGEM-T or primers complementary to the cDNA encoding the GABA B receptor were used. EXAMPLE ID : Cloning and sequencing of the 5 '-end of the cDNA encoding human GABA B receptor 1 a Messenger RNA from human hippocampus was obtained from Clontech (Palo Alto, USA) (catalogue #6578-1). Marathon cDNA amplification Kit (Clontech) was used to obtain adaptor-ligated double stranded cDNA molecules according to the manufacturer's description. The pd(N) 6 primer from the First-strand cDNA Synthesis kit-from Amersham Pharmacia Biotech (Uppsala, Sweden) was used to obtain the adaptor-ligated cDNA . Specific PCR primers were designed (Table 4) based on the sequences of the human GABA B receptor la cDNA obtained in Example 1 and the rat GABA B receptor la cDNA disclosed in WO 97/46675. TABLE 4 Primers used to amplify 5 '-ends of the human GABAB receptor la cDNA cDNA fragments encoding part of the human GABAB la receptor were amplified directly by PCR using the designed primers with the generated adaptor-ligated cDNA molecules as template. The PCR was performed using the Perkin Elmer Taq DNA polymerase with Gene Amp (Roche Molecular Systems Inc., NJ, USA) with the following PCR program: +94°C for 1 minute, +50°C for 30 seconds,+72°C for 3 minutes; +94°C for 1 minute, +60°C for 30 seconds,+72°C for 4 minutes, repeated 34 times and finally +72°C for 7 minutes. The primer combination 1087 and 1033 gave a PCR product corresponding to the 5.'-end of the GABA B receptor la cDNA , including 26 base pairs upstream the initiation codon. The PCR products were subcloned into the pGEM-T vector from Promega (Madison, USA). The inserts were subjected to nucleotide sequence analysis, the complete nucleotide sequence for all subclones were determined using a Thermo Sequenase dye terminator cycle sequencing pre-mix kit (Amersham Pharmacia Biotech, Uppsala, Sweden). As primers for sequencing reactions specific oligonucleotides complementary to the vector pGEM-T were used. A complete cDNA sequence encoding the human GABAB receptors la (SEQ ED NO: 48) and the human GABAB receptor lb (SEQ ID NO: 50) were obtained by aligning the sequences of the different fragments cloned and sequenced in Examples 1A, IB, 1C and ID. EXAMPLE 2A: Cloning and sequencing of cDNA encoding canine GABAB receptor la QuickPrep Micro mRNA Purification kit (Amersham Pharmacia Biotech, Uppsala, Sweden) was used to isolate mRNA from canine neural tissues according to the manufacturers description. First-strand cDNA synthesis reactions were performed using the First-strand cDNA Synthesis kit from Amersham Pharmacia Biotech (Uppsala, Sweden). The Not-I-d(T)ι 8 bifunctional or pd(N) 6 primer was used to prime the first-strand synthesis. The generated cDNA molecules were used as template in the PCR reactions described below. Specific PCR primers (Table 5) were designed based on the sequences of the rat GABA B receptor la and lb cDNA (Kaupmann et al. 1997, EMBL accession numbers Y 10369 (SEQ ID NO: 44 and Y10370 (SEQ ID NO: 46)). TABLE 5 Primers used for RT-PCR on mRNA from canine cortex cDNA fragments encoding parts of the canine GAB Aβ receptor were amplified directly by PCR using the designed primers with the generated cDNA molecules as templates. All PCR experiments were carried out using the Perkin Elmer Taq DNA polymerase with Gene Amp (Roche Molecular Systems Inc., NJ, USA) with the following PCR program: +95°C for 1 minute, +50°C for 30 seconds, +72°C for 3 minutes, repeated 44 times and finally +72°C for 7 minutes. The following primer combinations gave PCR products with expected sizes: 842 and 838, 838 and 795, 838 and 865 which corresponds to the 5 '-part of the canine GABA B receptor cDNA . Primer pair 848 and 844, 848 and 831, 848 and 841, 840 and 841 gave PCR products which correspond to the 3 '-part of the canine GABA β receptor cDNA. The PCR products were subcloned into the pGEM-T vector from Promega (Madison, USA). The inserts were subjected to nucleotide sequence analysis, the complete nucleotide sequence for all subclones were determined using a Thermo Sequenase dye terminator cycle sequencing pre-mix kit (Amersham Pharmacia Biotech, Uppsala, Sweden). As primers for sequencing reactions specific oligonucleotides complementary to the vector pGEM-T or primers complementary to the cDNA encoding the GABAg receptor were used. EXAMPLE 2B: Cloning and sequencing of the 3'- and 5 '-ends of the cDNA encoding canine GABA B receptor la QuickPrep Micro mRNA Purification kit (Amersham Pharmacia Biotech, Uppsala, Sweden) was used to isolate mRNA from canine nerve tissues according to the manufactures description. Marathon cDNA amplification Kit (Clontech, Palo Alto, CA, USA) were used for performing both 5 '-and 3 '-RACE. Two adaptor-ligated double stranded cDNA libraries were amplified according to the manufacturers description. A random primer (pd(N) 6 ) was used when amplifying the adaptor-ligated cDNA for the 5'- RACE and the Marathon cDNA Synthesis primer (52-mer) was used when amplifying the adaptor ligated cDNA for the 3 '-RACE. Specific PCR primers were designed (Table 6) based on the sequence of canine GABA B receptor la cDNA obtained in Example 2A. TABLE 6 Primers used in PCR to amplify the 5'- and 3 '-ends of canine GABA B receptor la cDNA cDNA fragments encoding parts of the canine GAB B receptor were amplified by PCR from the adaptor-ligated cDNA using the designed primers. A number of different PCR programs were tested to find conditions where PCR products corresponding to GABA B receptor DNA were obtained. The 5'- PCR experiments were carried out using the Expand Long Template PCR System (Boehringer Mannheim GmbH, Germany) with the following PCR program: +94°C for 30 seconds, +72°C for 3 minutes, repeated 4 times; +94°C for 30 seconds, +70°C for 3 minutes, repeated 4 times; and +94°C for 30 seconds, +68°C for 3minutes, repeated 24 times. The primer combination AP2 and 1076 gave a PCR product which corresponded to the 5 '-end of the GABA B receptor cDNA, including 1 14 base pairs upstream the initiation codon. The 3'- PCR experiments were carried out using the Expand Long Template PCR System (Boehringer Mannheim GmbH, Germany) with the following PCR program: +94°C for 1 minute; and +94°C for 30 seconds, +60°C for 30 seconds,+68 °C for 4 minutes, repeated 29 times. The primer combination API and 936 gave a PCR fragment which corresponded to the 3 '-end of the GABA B receptor cDNA, including the poly (A) tail. The PCR products were subcloned into the pGEM-T vector from Promega (Madison, USA). The inserts were subjected to nucleotide sequence analysis, the complete nucleotide sequence for all subclones were determined using a Thermo Sequenase dye terminator cycle sequencing pre-mix kit( Amersham Pharmacia Biotech, Uppsala, Sweden). As primers for sequencing reactions specific oligonucleotides complementary to the vector pGEM-T or primers complementary to GABAs receptor DNA were used ' . Complete cDNA sequence encoding the canine GABAB receptor la (SEQ ID NO: 52) was obtained by aligning the sequences of the different fragments obtained in Example 2A and Example 2B. EXAMPLE 3 A: Cloning of cDNA encoding human GABAs receptor lc and Id from Jurkat cells A guanidinisothiocyanate/CsCl method was used to isolate total RNA from Jurkat cells. The first-strand cDNA synthesis was performed using the First-strand cDNA Synthesis kit from Amersham Pharmacia Biotech (Uppsala, Sweden). The pd(N) δ primer was used to prime the first strand synthesis. The generated cDNA molecules were used as templates in the PCR reaction described below. Specific PCR primers (Table 7) were designed based on the sequence of human GABAs receptor la and lb cDNA (Example 1), rat GABAβ receptor (Kaupmann et al. 1997) and the EST sequence EMBL accession number Yl 1044. TABLE 7 Primers used in RT-PCR on mRNA from Jurkat cells cDNA fragments encoding parts of the GABA B receptor were amplified directly by PCR using human and rat specific primers. All PCR experiments were carried out using the Perkin Elmer Taq DNA polymerase with Gene Amp (Roche Molecular Systems Inc., NJ, USA) with the following PCR program: +95°C for 1 minute; +54°C for 1 minutes, +72°C for 3 minutes, repeated 44 times; and finally +72°C for 7 minutes. The PCR products were subcloned into the pGEM-T vector from Promega (Madison, USA). The inserts were subjected to nucleotide sequence analysis, the complete nucleotide sequence for all subclones were determined using a Thermo Sequenase dye terminator cycle sequencing pre-mix kit (Amersham Pharmacia Biotech, Uppsala, Sweden). As primers for sequencing reactions specific oligonucleotides complementary to the vector pGEM-T or primers complementary to GABAs receptor DNA were used. The following primer combination gave PCR products corresponding to the 3 '-end of the GABA B receptor cDNA: primer pairs 938 and 972; 938 and 973. Unexpectedly both these fragments lacked 149 base pairs, resulting in a frame shift and the insertion of a new termination codon. The following primer combination gave a PCR product corresponding to the 5 '-part of the GABA B receptor la cDNA: 893 and 937. The primer pairs 1005 and 937, 1030 and 937 gave PCR products corresponding to the 5 '-part of the GABAs receptor lb cDNA. Also these PCR fragments lacked the same 149 base pairs which resulted in a frame shift and the insertion of a new termination codon. These results show that Jurkat cells contain mRNA encoding two new forms of the human GABAs receptor. These are designated GABAs receptor lc (SEQ ID NO: 54 and 55) (comprising the same 5 '-part as the GABA B receptor la) and GABA B receptor Id (SEQ ID NO: 56 and 57) (comprising the same 5 '-part as the GABA B receptor lb). These two forms of the GABA B receptor do not contain any of the transmembrane regions and are therefore expected to be soluble forms of the receptor. EXAMPLE 3B : Analysis of cDNA encoding human GABAs receptors from hippocampus Messenger RNA from human hippocampus was obtained from Clontech (Palo Alto, USA) (catalogue #6578-1). First strand cDNA synthesis reactions were performed using the First- strand cDNA Synthesis kit from Amersham Pharmacia Biotech (Uppsala, Sweden). The pd(N) 6 primer was used to prime the first-strand synthesis. The generated cDNA molecules were used as template in the PCR reactions described below. Specific PCR primer was designed (Table 8) based on the sequences of the cDNAs encoding human GABA B receptors la and lb. TABLE 8 Primers used for RT-PCR on mRNA from human hippocampus cDNA fragments encoding parts of the human GABA B receptors were amplified directly by PCR using the designed primers with the generated cDNA molecules as templates. All PCR experiments were carried out using the Perkin Elmer Taq DNA polymerase with Gene Amp (Roche Molecular Systems Inc., NJ, USA) with the following PCR program: +94°C for 1 minute, +50°C for 30 seconds,+72°C for 3 minutes; +94°C for 1 minute, +54°C for 30 seconds, +72°C for 3 minutes repeated 44 times; and finally +72°C for 7 minutes. The primer combination 938 and 937 gave a PCR product which corresponded to the expected size of the GABA B receptor la and lb cDNA but also a fragment a smaller size. The PCR products were subcloned into the pGEM-T vector from Promega (Madison, USA). The inserts were subjected to nucleotide sequence analysis, the complete nucleotide sequence for all subclones were determined using a Thermo Sequenase dye terminator cycle sequencing pre-mix kit (Amersham Pharmacia Biotech, Uppsala, Sweden). As primers for sequencing reactions specific oligonucleotides complementary to the vector pGEM-T or primers complementary to the cDNA encoding the GABA B receptor were used. The larger PCR fragment was found to correspond to the 3 '-part of the GABA B receptor la and lb cDNA and the smaller fragment which lacked 149 base pairs was found to correspond to the 3 '-part of the GABA B receptors lc and Id cDNA identified in Example 3A. EXAMPLE 4: Cloning and sequencing of cDNA encoding canine GABAB receptor lb cDNA encoding the canine GABA B receptor lb is isolated in a similar manner as described in Example 2 for receptor la. PCR primers specifically designed to be complementary to the 5 '-end of the cDNA encoding the rat and human GABAB receptor lb, together with PCR primers complementary to the 3 '-end of the cDNA encoding the canine GABA B receptor la, and mRNA prepared from a suitable canine tissue, are used. EXAMPLE 5: Cloning of cDNA encoding canine GABAs receptor lc Total RNA from canine liver was prepared using the RNeasy Total RNA Purification Protocols (Quiagen GmbH, Germany). The first-strand cDNA synthesis was performed using the First-strand cDNA Synthesis kit from (Amersham Pharmacia Biotech, Uppsala, Sweden). The pd(N) 6 primer was used to prime the first -strand synthesis. The generated cDNA molecules were used as templates in the PCR reaction described below. Specific PCR primers (Table 9) were designed based on the sequence of canine GABAs receptor la cDNA. TABLE 9 Primers used in RT-PCR i cDNA fragments encoding parts of the canine GABAs receptor were amplified directly by PCR using canine specific primers. All PCR experiments were carried out using the Perkin Elmer Taq DNA polymerase with Gene Amp (Roche Molecular Systems Inc., NJ, USA) with the following PCR program: +95°C for 1 minute, +54°C for 30 seconds, +72°C for 3 minutes, repeated 44 times and finally +72°C for 7 minutes. The primer combination gave a PCR product with a size corresponding to the GAB A B receptor 1 a but also a fragment of smaller size indicating the presence of a GABA B receptor lc. The PCR products were subcloned into the pGEM-T vector from Promega (Madison, USA). The inserts were subjected to nucleotide sequence analysis, the complete nucleotide sequence for all subclones were determined using a Thermo Sequenase dye terminator cycle sequencing pre-mix kit (Amersham Pharmacia Biotech, Uppsala, Sweden). As primers for sequencing reactions specific oligonucleotides complementary to the vector pGEM-T were used. The smaller fragment was shown to lack 149 base pairs. This deletion caused a frame shift and an insertion of a new termination codon, verifying the existence of a canine GABA B receptor lc. Complete cDNA sequence encoding the canine GABA B receptor lc (SEQ ID NO: 58) was obtained by aligning the sequences of the fragments obtained in Example 2A, Example 2B and Example 5. EXAMPLE 6. Cloning, sequencing and organization of human GABA B receptor genomic fragments To determine the structural organization and sequence of the human GABAs receptor gene, human genomic DNA libraries and human genomic DNA were screened and analyzed. Human genomic libraries were obtained from Clontech (Palo Alto, CA, USA). The libraries were constructed from female leukocyte DNA (catalog # HL1111 J), cloned into λEMBL-3 vector. The average size of inserts are 16 kb and the number of independent clones are 1.7x10^. Human genomic DNA was obtained from Clontech (catalog # 6550-1). In order to isolate recombinant phages containing exon and intron sequences of the human GABA B receptor gene, 48 individual bacterial plates with a diameter of 150 mm and approximately 4 x 10^ individual plaques per plate, were screened. The methods and solutions used were as described in the Library Protocol Handbook: General Procedures for the Hybridization of Lambda Phage Libraries w/DNA Probes (Clontech) with some modifications as will be apparent from the following. The experiment was carried out essentially as follows. The numbers are given per plate basis. A sample of the phage library diluted in 0.1 ml sterile lambda diluent was prepared in order to obtain an estimated titer of 40.000 pfu (plaque forming units). A 0.6 ml LB- medium culture of the E. coli host strain K802 (obtained from Clontech) was infected with 40000 pfu recombinant phages for 15 minutes at +37°C. The culture was then mixed with 7 ml top agarose (6.5 g of agarose added per liter LB) and poured onto LB plates. The plates were incubated at +37°C for approximately 7 hours. The plates were then chilled at +4°C. Plaque hybridization experiments were as follows. Membrane filters, Colony/Plaque Screen (DuPont, Wilmington, DE, USA), were placed onto the top of the plates for 3 minutes. For denaturation of DNA the filters were removed and floated in 0.5 M NaOH on a plastic wrap for 2 minutes, with the plaque side up. This step was repeated once to ensure efficient denaturation. Following neutralization the membrane filters were placed in 1M Tris-HCl pH 7.5, two times 2 minutes and allowed to dry. To obtain probes for DNA hybridization screening of the membrane filters, a GABA B receptor cDNA clone was digested with SacII and a 479 bp fragment (base pairs 573-1051 in the cDNA encoding human GABA B receptor la, SEQ ID NO: 48) was separated by agarose electrophoresis, excised and transferred to a polypropylene microcentrifuge tube. Additional probes were obtained by PCR amplification of various regions of the GABAs receptor cDNA (base pairs 68-486 and 2368-2863 in the cDNA encoding human GABAs receptor la, SEQ ID NO: 48). The isolated cDNA fragment was 32p-i a beled using Megaprime DNA labeling system (Amersham Pharmacia Biotech, Uppsala, Sweden) by the following procedure. Water was added at a ratio of 3 ml per gram of gel, and placed in a boiling water bath for 7 minutes to melt the gel and denature the DNA. A volume of DNA/agarose solution containing 25 ng of DNA was added to the labeling reaction, according to the supplier's instructions. Labeled nucleotides were removed from DNA labeling reactions using MicroSpin™ G-50 Columns (Amersham Pharmacia Biotech, Uppsala. Sweden ). The DNA hybridization reaction was performed under stringent conditions according to the method described below. The filter membranes were prehybridized at +65°C for at least 1 hour in a solution composed of 1% SDS, 1M NaCl, and 10% dextran sulfate using a hybridization oven (Hybaid Ltd, Ashford, UK). Following prehybridization a solution containing denatured herring sperm DNA of a final concentration of 100 μg/ml and the 32p-labeled DNA probe at a concentration <10 ng/ml (for optimal signal to background ratio) was added to the prehybridization solution and the membrane filters were incubated at +65°C for 10-20 hours. Following the removal of the hybridization solution the membrane filters were first washed in a 2xSSC (0.3M NaCl, 0.03M Na-citrate), 1% SDS solution two times for 5 minutes at room temperature. In the next step, the membrane filters were incubated +60°C two times for 30 minutes each in the same solution. In a third step, the filters were washed two times at room temperature in O.lxSSC. Finally, the membrane filters were placed on a sheet of filter paper with the DNA face up, and allowed to dry. The dried membrane filters were then exposed to X-ray films and autoradiographed. Of the approximately 2x10^ individual plaques analyzed, four hybridizing plaques were detected and isolated. These three isolates were designated #GR1, #GR12, #GR13 and #GR41, respectively. After several rescreening experiments, the recombinant phage DNA was purified using Qiagen Lambda Midi Kit (Qiagen GmbH, Germany). The purified DNA was digested with Sail and the fragments representing the inserts were isolated by agarose electrophoresis. The sizes of the inserts were approximately isolate #GR1, 12 kb, isolate #GR12, 12 kb; isolate #GR13, 16kb; and isolate #GR41, 19 kb. These fragments were cloned into Sail digested linearized pUC19, resulting in the plasmids pAM362 (isolate #GR1), pAM363 (isolate #GR12), pAM364 (isolate #GR13)and pAM365 (isolate #GR41). The inserts from the four plaques which hybridizes to the GABAs receptor cDNA probes were analyzed by PCR, restriction mapping and hybridization to 32p . i a beled DNA fragments representing various regions of the GABAs receptor gene. The cloned fragments in the plasmids pAM362, pAM363, pAM364 and pAM365 were characterized by restriction enzyme mapping, using EcoRI, Hindiπ, Pstl, and BamHI. The approximate positions of the exons and the approximate size of the introns were analyzed and determined by PCR-based exon-exon linking and agarose gel electrophoresis. In order to facilitate nucleotide sequence analysis, 7 restriction sub-fragments derived from pAM364, 2 restriction fragments derived from pAM362, and 1 restriction sub-fragment derived from pAM365 were isolated and cloned into pUC19, resulting in the plasmids pAM366-pAM375. The following strategy was employed; by combining PCR primers located within the pUC19 sequence either upstream or downstream of the cloning site, with a PCR primer with defined orientation and specific for the GABA B receptor derived subcloned fragment allowed the determination. The inserts in the 10 plasmids pAM366-pAM375 were subjected to nucleotide sequence analysis. The nucleotide sequences for all subclones were determined using a Thermo Sequenase dye terminator cycle sequencing pre-mix kit (Amersham Pharmacia Biotech, Uppsala, Sweden). As primers for sequencing reactions specific oligonucleotides complementary to pUC19 or primers complementary to the GABA B receptor cDNA were used. The genomic fragments cloned in the plasmids pAM362-pAM365 where shown to contain the complete transcribed part of the human GABA B receptor gene and extends > 3kb upstream of the first exon and > 2kb downstream of the last exon. The fragments cloned in the plasmid pAM362 were shown to contain exons 7-11, pAM363 exons 12-22, pAM364 exons 1-11, and pAM365 exons 12-23 of the GABA B receptor gene (Figure 1). The sequence of exons 1-11 and introns 1-10 is listed in SEQ ID NO: 60 and the sequence of exons 12-23 and introns 12-22 is listed in SEQ ID NO: 61. The human GABA B receptor gene consists of 23 exons and 22 introns (Figure 1). The size of the exons range between 21 bp and 1486 bp. As can be noted from Table 10 exon/intron boundaries are in accordance with the AG/GT rule and conform well to the consensus sequence suggested by Mount et al. 1982. TABLE 10 Exon-Intron boundaries of the GABA B receptor gene, sequences at exon-intron junctions. 5 'splice donor 3 'splice acceptor Exon 1-Exon 2 CGAG GTAAGAG CCGCCTCTCACTTAG ATGT Exon 2-Exon 3 GAAG GTGCATC CGACTCACCCCTTAG GTTG Exon 3-Exon 4 TQTG GTGAGTA. CCWATCTCTCCACAG TCCG Exon -Exon 5 CΛGG GTGAGGG CTTTCCTGCTGCCAG TGAA Exon 5-Exon 6 TCAG GTGAGAT CGCACCCCTCCTCAG AACG Exon 6-Exon 7 CAAG GTAGCCC CCTCTTGTCTTTCAG TGTG Exon 7-Exon 8 TGTG GTAAGCA. CTCCCTGCCCCACAG CTTT Exon 8-Exon 9 T CG GTGAGGA. TTATTCCCACCCAAG ACTC Exon 9-ExonlO GAAG GTCAGAT CTTTCTCTGTKGTAG CGCC ExonlO-Exonll TGAG GTGGART CTCCTCTGTATTCAG GTGT Exonll-Exonl2 CATG GTGAGAG TTTTTTCCTCCCAAG ACAT Exonl2-Exonl3 CTCT GTGAGTT TGTTCCTTCCCTCAG GGCC Exonl3-Exonl4 CAGG GTTAGTA. TTGTCGTCTGCCCAG GTGG Exonl4-Exonl5 AT G GTGAGTG ., CCCTGTGCCATGCAG GAGG Exonl5-Exonl6 TCCG GTXAGTT CCACCTCTGCCCTAG TTAT Exonlβ-Exonl7 CCAG GTGAGGA TCTCTTCCTTTCTAG GCCC Exonl7-Exonlβ GAAG GTGAGCT CACATATTTATCCAG ACTC Exonl8-Exonl9 TGAG GTACCAC TYGTTTCTGCCCTAG ACAT Exonl9-Exon20 CTTG GTGTGTG CTCCTGCCATCCTAG GCAT Exon20-Exon21 GGCA GTGAGCA. TGTCTTTCCCTCTAG GTCC Exon21-Exon22 CAAG GTAAGGA AACATTTGCCCCCAG ATGC Exon22-Exon23 TGAG GTGCGGG TGCTTCTTCCTCCAG AAAG A comparison of the sequences of the different forms of the human GABAs receptor cDNA (SEQ ID NO: 48, 50, 54, and 56) and the sequence of the human GABAs gene (SEQ ID NO: 60 and 61) reveals that different mRNA encoding human GABA B receptors are formed by alternative splicing. The translational start of the GABA B receptor la is localized in exon 2 and the translational stop is localized in exon 23. The mRNA encoding GABAs receptor lb is formed by alternative splicing where part of intron 5 is retained together with exon 6 where the translational start of the GABA B receptor lb is derived from the intron sequence. The mRNA encoding GABA B receptor lc is formed by alternative splicing where exon 15 are removed together with introns 14 and 15 and a frame shift and a translational stop are generated in the sequence corresponding to exon 16. The mRNA encoding GABA B receptor Id is formed when the translational start of the GABA B receptor lb is generated together with the translational stop of the GABAs receptor lc. The la isoform is formed by splicing exon 5 to a cryptic splice site in the middle of exon 6. Transcription of lb isoform mRNA is most likely initiated from regulatory elements in intron 5. The ATG initiating translation of lb mRNA is located in the 5 '-end of exon 6. Additional variants of the mRNA encoding variants of the human GABAs receptor can be derived by alternative splicing where one ore more of the exons or part of exons are excised in the processing of the pre-mRNA. The subsequent transcription of these mRNA will give rise to variants of the human GABA B receptor with potentially different biological and/or pharmacological activities. EXAMPLE 7. Analysis of cDNA encoding human GABA B receptors from human brain Messenger RNA from human fetal brain (catalog #6525-1) and adult human brain (catalog #6516-1) were obtained from Clontech (Palo Alto, CA, USA). First strand cDNA synthesis reactions were performed using the first strand cDNA Synthesis kit from Amersham Pharmacia Biotech (Uppsala, Sweden).The pd(N) 6 primer was used to prime the first- strand synthesis. The generated cDNA molecules were used as templates in the PCR reactions described below. Specific PCR primers was designed (Table 11 ) based on the sequences of the rat GABAs receptor la and lb cDNA and human GABA B receptor la and lb cDNA TABLE 11 Primers used for RT-PCR on mRNA from human fetal brain cDNA fragments encoding parts of the human GABA B receptors were amplified directly by PCR using the designed primers with the generated cDNA molecules as templates. PCR experiments with primers 838, 863 ,864 and 865 were carried out using the Perkin Elmer Taq DNA polymerase with Gene Amp (Roche Molecular System Inc., NJ, USA) with the following PCR program: +95°C for 1 minute, +50°C for 30 seconds,+72°C for 3 minutes, repeated 44 times and finally +72°C for 7 minutes. PCR experiments with primers 937 and 1015 were carried out using the Expand Long Template PCR System (Boehringer Mannheim GmbH, Germany) with the following PCR program: +94°C for 2 minutes; +94°C for 10 seconds, +55°C for 30 seconds, +68°C for 3 minutes repeated 35 times; and finally +68°C for 7 minutes. The primer combinations 838 and 863, 864 and 863 , 864 and 865, 937 and 1015 gave PCR products. The PCR products were subcloned into the pGEM-T vector from Promega (Madison, WI, USA). The inserts were subjected to nucleotide sequence analysis. The complete nucleotide sequence for all subclones were determined using a ThermoSequenase dye terminator cycle sequencing pre-mix kit (Amersham Pharmacia Biotech, Uppsala, Sweden). As for primers for sequencing reactions specific oligonucleotides complementary to the vector pGEM-T or primers complementary to the cDNA encoding the GABA B receptor were used. A number of analyzed clones isolated from fetal brain were found to lack 186 base pairs, corresponding to exon 4. This alternative splicing resulted in a cDNA (SEQ ID NO: 70) encoding a protein (SEQ ID NO: 71) comprising of 899 amino acids and designated GABAs receptor le. Other clones from fetal brain lacked 368 base pairs, corresponding to exons 4, 5 and 6, resulting in a cDNA (SEQ ID NO: 72) where a frame shift and a translational stop codon are generated in the sequence corresponding to exon 7, encoding a protein (SEQ ID NO: 73) comprising only 97 amino acids designated GABA B receptor lf. One clone lacked 207 base pairs, corresponding to exons 4 and 5, resulting in a cDNA (SEQ ID NO: 74) encoding a protein (SEQ ID NO: 75) comprising 892 amino acids designated GABA B receptor lg. Another clone had two deletions, the first comprising 186 base pairs corresponding to exon 4, the second comprising 39 base pairs corresponding to part of exon 6, resulting in a cDNA (SEQ ID NO: 76) encoding a protein (SEQ ID NO: 77) comprising 886 amino acids designated GABA B receptor lh. Yet another clone from adult human brain was found to have a long deletion comprising 1194 base pairs corresponding to base pairs 319 - 1512 of the cDNA encoding human GABAs receptor 1 a. This deletion corresponds to part of exon 4, exons 5-1 1, and part of exon 12. This cDNA (SEQ ID NO: 78) encodes a protein (SEQ ID NO: 79) comprising 563 amino acids designated GABA B receptor li. One clone isolated from fetal brain lacked 284 base pairs corresponding to part of exon 3 and the whole exon 4, generating a frame shift and a translational stop codon in the sequence corresponding to exon 5. This cDNA (SEQ ID NO: 80) encodes a protein (SEQ ID NO: 81) comprising only 105 amino acids designated GABAs receptor lj. EXAMPLE 8. Analysis of cDNA encoding human GABAs receptors from Jurkat cells A guanidinisothiocyanate/CsCl method was used to isolate total RNA from Jurkat cells. First strand cDNA synthesis reactions were performed using the first strand cDNA Synthesis kit from Amersham Pharmacia Biotech (Uppsala, Sweden).The pd(N)g primer was used to prime the first-strand synthesis. The generated cDNA molecules were used as templates in the PCR reactions described below. Specific PCR primers was designed (Table 12) based on the sequences of the human GABA B receptor la and lb cDNA TABLE 12 Primers used for RT-PCR on mRNA from Jurkat cells cDNA fragments encoding parts of the human GABA B receptors were amplified directly by PCR using the designed primers with the generated cDNA molecules as templates. The PCR experiment was carried out using the Expand Long Template PCR System (Boehringer Mannheim GmbH, Germany) with the following PCR program: +94°C for 2 minutes; +94°C for 10 seconds, +55°C for 30 seconds, +68°C for 3 minutes repeated 35 times; and finally +68°C for 7 minutes. The primer combination 937 and 1015 gave a PCR product. The PCR products were subcloned into the pGEM-T vector from Promega (Madison, WI, USA). The inserts were subjected to nucleotide sequence analysis. The complete nucleotide sequence for all subclones were determined using a ThermoSequenase dye terminator cycle sequencing pre-mix kit (Amersham Pharmacia Biotech, Uppsala, Sweden). As for primers for sequencing reactions specific oligonucleotides complementary to the vector pGEM-T or primers complementary to the cDNA encoding the GABA B receptor were used. Two clones had two deletions, the first comprising 368 base pairs corresponding to exons 4, 5 and 6, the second comprising 151 base pairs corresponding to exon 15 where a frame shift and a translational stop codon are generated in the sequence corresponding to exon 7. This cDNA (SEQ ID NO: 82) encodes a protein (SEQ ID NO: 83) comprising only 98 amino acids designated GABAB receptor Ik which is identical to the GABA B receptor lf described above. Another two clones also had two deletions, the first comprising 246 base pairs corresponding to part of exon 4, exon 5 and exon 6, the second comprising 149 base pairs corresponding to exon 15, generating a frame shift and a translational stop codon in the sequence corresponding to exon 16. This cDNA (SEQ ID NO: 84) encodes a protein (SEQ ID NO: 5) comprising 496 amino acids designated GABAs receptor 11. Additional variants of cDNA encoding the human GABA B receptors can be identified in a similar manner using PCR primers based on the sequence of the cDNA and genomic fragments encoding the human GABA B receptors disclosed in the present application. The biological activity of these variants of the human GABA B receptor can be evaluated by transfection of suitable host cells with expression vectors comprising the corresponding cDNA sequences and subsequent measurement of binding of labeled ligands or activation of the receptor or modulation of receptor function. EXAMPLE 9: Generation of antibodies Antibodies were raised in rabbits against four different BSA-conjugated 20 amino acids long synthetic peptides corresponding to selected regions of the human and canine GABA B receptor extracellular domain. Two were directed against a sequence common for GABA B receptor la and b (abl and ab2), one against a GABA B receptor la-specific region (al) and one against a GABA B receptor lb-specific sequence (bl). To allow BSA-conjugation, a cystein residue was added to the N-terminus in all peptides but al, which contains an endogenous cystein. Peptide al : (SEQ ID NO: 49 amino acids 18-37) Gly Gly Ala Gin Thr Pro Asn Ala Thr Ser Glu Gly Cys Gin He IleJHis Pro Pro Trp Peptide ab 1 : (SEQ ID NO: 49 amino acids 197-216 with N-terminally added Cys) Cys - Glu Asp Val Asn Ser Arg Arg Asp He Leu Pro Asp Tyr Glu Leu Lys Leu He His His Peptide ab2: (SEQ ID NO: 49 amino acids 271 -290 with N-terminally added Cys) Cys - Ser Pro Ala Leu Ser Asn Arg Gin Arg Phe Pro Thr Phe Phe Arg Thr His Pro Ser Ala Peptide bl: (SEQ ID NO: 57 amino acids 30-47 with N-terminally added Cys) Cys - Ser His Ser Pro His Leu Pro Arg Pro His Ser Arg Val Pro Pro His Pro Ser The antibodies were purified from rabbit serum by affinity chromatography using the corresponding immobilized peptide and subsequently used to detect expression of recombinant GABA B receptor isoforms on Western blots. EXAMPLE 10: Heterologous expression of GABA B receptor isoforms in mammalian cells A Hindiπ / Sail cDNA fragment encoding the human GAB A 3 receptor lb isoform was cloned into a BPV (bovine papilloma virus)-based expression vector containing the mMT- 1 (murine metallothioneine) promoter. Using the calcium phosphate method, murine C127 cells were co-transfected with the GABA B receptor expression construct and an expression plasmid containing a G418 resistance marker gene using the calcium phosphate method. G418 resistant clones were evaluated by Western blot analysis for expression of the approximately 100 kDa GABA B receptor lb isoform(Figure 2). Similarly, but using Lipofectamine (Life Technologies Inc, Rockville, MD, USA) for transfection, the human GABAs receptor lb isoform was expressed in human HEK-293 cells using the pCI-neo expression vector. The identity of the heterologously expressed receptor was verified in HEK-293 cells by Western blot analysis and radiologand binding experiments. A cDNA fragment encoding the human GABA B receptor Id isoform was A cloned into a BPV-based expression vector containing the mMT- 1 promotor. Using the calcium phosphate method, murine C127 cells were co-transfected with the GABA B receptor expression construct and an expression plasmid containing a G418 resistance marker gene. G418 resistant clones, and concentrated medium from the same clones, were evaluated for GABA B receptor Id isoform expression by Western blot analysis (Figure 3). The experiment revealed the human GABAs receptor Id to be a secreted isoform. EXAMPLE 11 : Heterologous expression of GABA B receptor isoforms in E. coli A cDNA fragment encoding the human GABA B receptor Id isoform was cloned into a modified pET (Pharmacia Amersham, Uppsala, Sweden) vector downstream of a STII (heat stable enterotoxin II of E. coli) signal peptide and followed by a thrombin clevage site and a hexahistidine tag. The expression construct was subsequently used to transform the BL21 (DE3) E. coli strain. Western blot analysis of IPTG-induced bacteria revealed expression of a human GABA B receptor Id isoform of expected size(Figure 4). In addition, the human GABAs receptor Id isoform was successfully expressed without fusion to a bacterial signal peptide in E. coli strain AD494 (DE3). EXAMPLE 12: Method for the screening of substances which are GABAB receptor antagonists or agonists GABAβ receptor expressing cells, transgenic animals or cells and tissues derived thereof, are used to screen substance libraries for antagonist or agonist activities. Screening is performed as ligand binding assays or functional assays. For screening, cells and tissues are prepared in various ways, each uniquely suited to its purpose. Ligand binding assays are performed in vivo or in vitro. Functional assays exemplified by, but not limited to, Ca ++ - responses, cAMP-responses and effects on Cl ~ and K + channels, are performed in living cells, broken cells, isolated cell membranes, as well as in tissues and in living animals.

Claims: CLAIMS 1. A nucleic acid molecule encoding a human or canine GABAR receptor, or a functionally equivalent modified form thereof. 2. A nucleic acid molecule according to claim 1 encoding a human GABAR receptor, or a functionally equivalent modified form thereof. 3. A nucleic acid molecule according to claim 2 encoding the human GABAR receptor la, or a functionally equivalent modified form thereof. 4. A nucleic acid molecule according to claim 3 selected from: (a) a nucleic acid molecule comprising a nucleotide sequence set forth as SEQ ID NO: 48; (b) a nucleic acid molecule comprising a nucleotide sequence capable of hybridizing, under stringent hybridization conditions, to a nucleotide sequence complementary to the polypeptide coding region of a DNA molecule as defined in (a); and (c) a nucleic acid molecule comprising a nucleotide sequence which is degenerate as a result of the genetic code to a nucleotide sequence as defined in (a) or (b). 5. A nucleic acid molecule according to claim 2 encoding the human GABAR receptor lb, or a functionally equivalent modified form thereof.. 6. A nucleic acid molecule according to claim 5 selected from: (a) nucleic acid molecules comprising a nucleotide sequence set forth as SEQ ED NO: 50; (b) nucleic acid molecules comprising a nucleotide sequence capable of hybridizing, under stringent hybridization conditions, to a nucleotide sequence complementary the polypeptide coding region of a DNA molecule as defined in (a); and (c) nucleic acid molecules comprising a nucleotide sequence which is degenerate as a result of the genetic code to a nucleotide sequence as defined in (a) or (b). 7. A nucleic acid molecule according to claim 2 encoding the human GABAR receptor lc, or a functionally equivalent modified form thereof. 8. A nucleic acid molecule according to claim 7 selected from: (a) nucleic acid molecules comprising a nucleotide sequence set forth as SEQ ID NO: 54; (b) nucleic acid molecules comprising a nucleotide sequence capable of hybridizing, under stringent hybridization conditions, to a nucleotide sequence complementary the polypeptide coding region of a DNA molecule as defined in (a); and (c) nucleic acid molecules comprising a nucleotide sequence which is degenerate as a result of the genetic code to a nucleotide sequence as defined in (a) or (b). 9. A nucleic acid molecule according to claim 2 encoding the human GABAR receptor Id, or a functionally equivalent modified form thereof.. 10. A nucleic acid molecule according to claim 9 selected from: (a) nucleic acid molecules comprising a nucleotide sequence set forth as SEQ ID NO: 56; (b) nucleic acid molecules comprising a nucleotide sequence capable of hybridizing, under stringent hybridization conditions, to a nucleotide sequence complementary the polypeptide coding region of a DNA molecule as defined in (a); and (c) nucleic acid molecules comprising a nucleotide sequence which is degenerate as a result of the genetic code to a nucleotide sequence as defined in (a) or (b). 11. A nucleic acid molecule according to claim 1 encoding a canine GABAR receptor, or a functionally equivalent modified form thereof. 12. A nucleic acid molecule according to claim 11 encoding the canine GABAR receptor la, or a functionally equivalent modified form thereof. 13. A nucleic acid molecule according to claim 12 selected from (a) nucleic acid molecules comprising a nucleotide sequence set forth as SEQ ID NO: 52; (b) nucleic acid molecules comprising a nucleotide sequence capable of hybridizing, under stringent hybridization conditions, to a nucleotide sequence complementary the polypeptide coding region of a DNA molecule as defined in (a); and (c) nucleic acid molecules comprising a nucleotide sequence which is degenerate as a result of the genetic code to a nucleic acid sequence as defined in (a) or (b). 14 A nucleic acid molecule according to claim 11 encoding the canine GABAR receptor lc, or a functionally equivalent modified form thereof. 15. A nucleic acid molecule according to claim 14 selected from (a) nucleic acid molecules comprising a nucleotide sequence set forth as SEQ ID NO: 58; (b) nucleic acid molecules comprising a nucleotide sequence capable of hybridizing, under stringent hybridization conditions, to a nucleotide sequence complementary the polypeptide coding region of a DNA molecule as defined in (a); and (c) nucleic acid molecules comprising a nucleotide sequence which is degenerate as a result of the genetic code to a nucleic acid sequence as defined in (a) or (b). 16. A recombinant polypeptide encoded by a nucleotide sequence according to any one of claims 1 to 15. 17. The polypeptide according to claim 16 comprising an amino acid sequence set forth as SEQ ID NO: 49, 51 , 53, 55, 57 or 59 in the Sequence Listing. 18. A polypeptide according to claim 16 which has been posttranslationally modified. 19. A vector transformed with a nucleic acid molecule according to any one of claims 1 to 15. 20. A cultured host cell harboring a vector according to claim 19. 21. A process for the production of a GABAR receptor, said process comprising culturing a host cell according to claim 20 under conditions whereby the said polypeptide is produced, and recovering the said polypeptide. 22. A method for the screening of compounds which are inhibitors of transient lower esophageal sphincter relaxations, said method comprising the use of a nucleic acid molecule encoding a GABAR receptor. 23. A method according to claim 22 wherein the said nucleic acid molecule encoding a GABAR receptor is the nucleic acid molecule according to any one of claims 1 to 15. 24. A method for the screening of compounds which are agonists or antagonists to a GABAR receptor, said method comprising the use of a nucleic acid molecule according to any one of claims 1 to 15. 25. A method according to any one of claims 22 to 24 comprising the steps (a) transforming a cultured cell with a nucleic acid molecule encoding a GABAR receptor, so that a GABAR receptor is expressed on the surface of the cell; (b) contacting a test compound with the said cell; and (c) determining whether the test compound binds to, and or activate, the GABAR receptor. 26. A pharmaceutical compositions comprising a soluble GABA B receptor further comprising one or more pharamceutical acceptable carriers and/or diluents.

Inventors: EKSTRAND JONAS, EKSTRAND, JONAS
Applicants: ASTRA AB, EKSTRAND JONAS, ASTRA AKTIEBOLAG, EKSTRAND, JONAS
Application year: 1998
Main classification: C07K14
IPC codes: A61K38, C07K14